Eli Lilly, Baxter: Risk-Mitigated Exposure to Alzheimer's Treatment

Speculation on the future of Alzheimer’s treatments has been at the forefront of major pharma and biotech news this month. Pfizer (NYSE:PFE) and Elan’s (NYSE:ELN) partnered compound bapineuzumab failed to reach its primary endpoint in a Phase III study treating Alzheimer’s this month, although a second Phase III trial should report by year’s-end. StemCells Inc. (NASDAQ:STEM) announced positive findings in a pre-clinical animal model treating an Alzheimer’s similar with human neural stem cells. We took a look at a few Alzheimer’s plays and identified two that have significant upside potential with compelling risk profiles. (more…)